• Developed and executed company strategy for Solaris Endovascular, driving global sales and achieving profitability.• Managed product portfolio and clinical trial execution to ensure successful outcomes.• Led capital fundraising efforts to secure necessary funding for company growth.

Recruited to lead an early-stage, research-focused company with unique technology based for allogenic platelet rich plasma (“PRP”). Spearheaded shift from a research organization to a product development and revenue-generating company. Created and drove a new corporate vision and strategy including creating value by employing clinical/regulatory progression and a clear path to exit.• Sole Responsibility for Series “B & C” rounds of private financing ($30M+).• Recruited a high-performing executive bench with specific experience with blood-based products and BLA’s (FDA: CBER). • Led Carmell through public listing process on a $150M valuation in July 2023 and quickly added a commercial stage company with Carmell Corporation the surviving entity (NASDAQ: CTCX).• Advanced two product candidates into development – Bone Healing Accelerant (BHA) & Tissue Healing Accelerant (THA).

Overall responsibility for creating and driving an “Integrated Commercial Model” that served as the blueprint for the commercial organization. Includes organizational design, implementation, and execution.• Participated in delivering a $25M Series “A” round of funding.• Led the “Commerce Team” to create a unique and pivotal value proposition allowing Cardiva Medical Sales Representatives to gain access and account penetration with both the clinical and administrative buyers of a hospital.• Achieved all fundraising objectives for 2014 determined by achieving significant commercial milestones, revenue growth, and projections to profitability. • Cardiva achieved a successful exit of a $510M acquisition by Hemonetics.

Selected to lead and drive the global marketing strategy for Ethicon Biosurgery. Established strategic plans, managed new product development portfolio, and globalized business in the $2B market for hemostasis products and surgical sealants. Assessed market needs/opportunities and drove idea innovation with R&D that led to significant global growth. Managed global marketeers and the development of localized branding, messaging, product positioning, launch strategies and processes. Collaborate with country-based leaders and improved launch and commercialization processes.• Created a Portfolio Management Committee (PMC) that consisted of a cross-functional executive team including R&D, Finance, Regulatory, Legal, Clinical, and Operations. This established a formal decision making and prioritization system for product funding/development. Delivered a solid launch cadence of products and boasted a rich pipeline of consecutive product launches dwarfing competing medical device companies. • Designed and implemented a Step-by-Step Biosurgery Sales Playbook that customized the business case and process that led to the creation of a dedicated sales force devoted to the biosurgery products. Grew the number of country based, dedicated Biosurgery, sales organizations from 10 to 30 countries; grew worldwide dedicated Biosurgery sales reps from 180 to 500+ in 2013.• Launch Excellence - Created and implemented a robust, systematic, and measurable approach to launch new products in markets globally. • Upstream Value Creation Model - Created and installed a new approach to customer generated insights to drive new product concepts that augment the traditional engineering-driven approach.• Commercial Acquisition & Integration Leader - Analyzed strategic fit of prospective acquisitions, developed forecasts, and ran business cases. Led integration strategies including branding, training, and process alignment.

Promoted into this role to create and drive a long-term strategy that would ignite profitability and the brand for the pain therapeutic area. Led and managed marketing activities for established global brands and new products under development; including positioning, messaging, segmentation, competitive strategy and launch planning.• Commercial leader that influenced J&J senior management via analytical justification to successfully bid and obtain the rights for the licensing of Amgen’s “anti-NGF,” monoclonal antibody, AMG-403. Business creativity to grow sales beyond J&J offerings. Global Marketing Leader - IONSYS™ - Pharmaceuticals Group Strategic Marketing (PGSM) (2005 – 2007) Promoted to hold worldwide responsibility for worldwide product launch including brand development and launch planning to introduce a transformational ion patch drug/device combination product for post-operative pain management.• Successfully launched product in 28 European countries.

Executive Director Strategic Alliances - Cordis Cardiology, Miami Lakes, FL (2004 – 2005)Creator and leader of an unprecedented joint venture and co-promotion agreement of CYPHER® with key competitor, Guidant. Author of the “Go-to-market” strategy to drive sales and market share. Director, US Stent Marketing (Launch Leader) - CYPHER® Sirolimus-Eluting Coronary Stent (2001 – 2004) Groundbreaking technology changing lives, saving significant healthcare $$. Overall responsibility for coronary stent marketing, including bare metal stents and overall marketing and launch responsibility for the first drug-eluting stent, CYPHER®.• Achieved $1B in US CYPHER sales in less than 8 months, 2003. Recognized with Standards of Leadership Award.• Led team in creating the worldwide brand footprint and the "Go-to-Market" pricing strategy.

Designed and installed the Sales, Marketing, Market Development and Marketing Communication functions at this venture capital funded start-up who delivered software and services for managing clinical trials.

Designed and installed the Sales, Marketing, Market Development and Marketing Communication functions at this venture capital funded start-up developing home dialysis products and access.

Developed and executed a global marketing strategy for a new segment, Vascular Access.• Negotiated and managed agreements/acquisition with companies that fulfilled segment’s needs.• Finished #1 in the company out of 75 territory managers for revenue percent growth (37%, 1994).

Sold entire IBM product line that included Hardware, Software and Professional Services and Consulting Services.• 100% Club Award Winner (for top 10% sales performers nationally), achieved in 4 separate years.